Sept 12 (Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said here.
Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment. (Reporting by Ismail Shakil in Bengaluru)
Our Standards: The Thomson Reuters Trust Principles.